Table 2.
Patient characteristics | LM mCRC patients with liver metastases | SD quality Cohorts CRC-FCSD and CRC-FSD No. (%) |
|||
---|---|---|---|---|---|
HQ quality | |||||
Cohort CRC-FCHQ-FC |
Cohort CRC-FHQ FOLFIRI |
||||
Training No. (%) | Validation No. (%) | Training No. (%) | Validation No. (%) | ||
Patients, no. | 78 | 38 | 78 | 51 | 288 |
Gender | |||||
Male | 50 (64.1) | 29 (76.3) | 51 (64.1) | 31 (60.8) | 184 (63.9) |
Female | 28 (35.9) | 9 (23.7) | 27 (34.6) | 20 (39.2) | 104 (36.1) |
Primary site | |||||
Right colon | 20 (25.6) | 14 (36.8) | 20 (25.6) | 17 (33.3) | 70 (24.3) |
Left colon | 58 (74.4) | 24 (63.2) | 58 (74.4) | 34 (66.7) | 217 (75.3) |
Prior adjuvant chemotherapy | |||||
Yes | 9 (11.5) | 6 (15.8) | 10 (12.8) | 6 (11.8) | 40 (13.9) |
No | 69 (88.5) | 32 (84.2) | 68 (87.2) | 45 (88.2) | 248 (86.1) |
Leucocytes | |||||
Low | 65 (83.3) | 35 (92.1) | 65 (83.3) | 34 (66.7) | 234 (81.3) |
High | 12 (15.4) | 3 (7.9) | 10 (12.8) | 15 (29.4) | 45 (15.6) |
LDH baseline | |||||
Low | 41 (52.6) | 18 (47.4) | 28 (35.9) | 21 (41.2) | 147 (51.0) |
High | 29 (37.2) | 15 (39.5) | 36 (46.2) | 21 (41.2) | 111 (38.5) |
Unknown | 8 (10.3) | 5 (13.2) | 14 (17.9) | 9 (17.6) | 30 (10.4) |
Maximum staining intensity | |||||
Low | 13 (16.7) | 1 (2.6) | 12 (15.4) | 7 (13.7) | 48 (16.7) |
High | 65 (83.3) | 37 (97.4) | 65 (83.3) | 44 (86.3) | 238 (82.6) |
Histology of primary tumor | |||||
Adenocarcinoma | 72 (92.3) | 35 (92.1) | 76 (97.4) | 50 (98.0) | 283 (98.3) |
Mucinous adenocarcinoma | 6 (7.7) | 3 (7.9) | 2 (2.6) | 1 (2.0) | 5 (1.7) |
Histological differentiation | |||||
Well differentiated | 10 (12.8) | 4 (10.5) | 15 (19.2) | 7 (13.7) | 33 (11.5) |
Moderately differentiated | 51 (65.4) | 24 (63.2) | 50 (64.1) | 33 (64.7) | 191 (66.3) |
Poorly differentiated | 15 (19.2) | 6 (15.8) | 12 (15.4) | 8 (15.7) | 44 (15.3) |
KRAS BRAF mutation status | |||||
KRAS mutant | 25 (32.1) | 19 (50.0) | 26 (33.3) | 17 (33.3) | 75 (26.0) |
KRAS and BRAF WT | 50 (64.1) | 15 (39.5) | 46 (59.0) | 31 (60.8) | 129 (44.8) |
BRAF mutant | 3 (3.8) | 4 (10.5) | 6 (7.7) | 3 (5.9) | 8 (2.8) |
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 76 (26.4) |
Target lesions at baseline, no. | |||||
0 | 0 (0.0) | 1 (2.6) | 0 (0.0) | 1 (2.0) | 2 (0.7) |
1 | 5 (6.4) | 5 (13.2) | 12 (15.4) | 3 (5.9) | 31 (10.8) |
2 | 9 (11.5) | 10 (26.3) | 13 (16.7) | 11 (21.6) | 45 (15.6) |
3 | 14 (17.9) | 7 (18.5) | 18 (23.1) | 11 (21.6) | 44 (15.3) |
4 | 13 (16.7) | 4 (10.5) | 5 (6.4) | 6 (11.8) | 43 (14.9) |
5 | 24 (30.8) | 7 (18.5) | 16 (20.5) | 10 (19.6) | 70 (24.3) |
>5 | 14 (17.9) | 4 (10.5) | 14 (17.9) | 10 (19.6) | 53 (18.4) |
Nontarget lesions at baseline, no. | |||||
0 | 17 (21.8) | 16 (42.1) | 20 (25.6) | 16 (31.4) | 77 (26.7) |
1 | 35 (44.9) | 8 (21.1) | 25 (32.1) | 16 (31.4) | 90 (31.3) |
2 | 10 (12.8) | 4 (10.5) | 22 (28.2) | 11 (21.6) | 50 (17.4) |
3 | 6 (7.7) | 6 (15.8) | 6 (7.7) | 4 (7.8) | 19 (6.6) |
4 | 2 (2.6) | 1 (2.6) | 2 (2.6) | 1 (2.0) | 13 (4.5) |
5 | 4 (5.1) | 2 (5.3) | 2 (2.6) | 1 (2.0) | 18 (6.3) |
>5 | 4 (5.1) | 1 (2.6) | 1 (1.3) | 2 (3.9) | 21 (7.3) |
Only liver metastasis | 57 (73.1) | 27 (71.1) | 49 (62.8) | 37 (72.5) | 211 (73.3) |
Only liver and lung metastasis | 63 (80.8) | 33 (86.8) | 73 (93.6) | 45 (88.2) | 253 (87.8) |
Liver metastatic patients included in the HQ cohorts have similar characteristics. The only difference is the quality of the CT scan acquisition protocol and reconstruction settings. The distribution of clinical characteristics for each subgroup of patients was compared using analysis of variance and χ2 (P values) and did not demonstrate any statistically significant difference between the cohorts. CT = computed tomography; CRC = colorectal cancer; F = FOLFIRI; FC = FOLFIRI+cetuximab; HQ = High computed tomography quality; SD = Standard computed tomography quality.